Sign in

Colorectal cancer: trials that stopped early

Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

    Reason given in the registry

    “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.

    Ended
    Feb 2024
    Phase
    Phase 1/2
    Run by
    Numab Therapeutics AG
    Registry record
    NCT04442126
  2. Withdrawn

    Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

    Reason given in the registry

    “Due to errors in the previously submitted modification, we request to withdraw it and will submit a corrected update shortly.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 May 2025.

    Ended
    Dec 2025
    Phase
    Phase 2
    Run by
    Sun Yat-sen University
    Registry record
    NCT06895577
  3. Terminated

    A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

    Reason given in the registry

    “Adjustment of the Company's R\&D Strategy”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 May 2025.

    Ended
    Apr 2024
    Phase
    Phase 2/3
    Run by
    Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    Registry record
    NCT04856787
  4. Terminated

    Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

    Reason given in the registry

    “Study terminated by sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    Hutchmed
    Registry record
    NCT04579757
  5. Terminated

    Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

    Reason given in the registry

    “PI Determination - Slow recruitment, funding concerns, poor response to treatment”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2025.

    Ended
    May 2024
    Phase
    Phase 2
    Run by
    University of Utah
    Registry record
    NCT04853043
  6. Terminated

    A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

    Reason given in the registry

    “Funding terminated due to business reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Apr 2025.

    Ended
    Mar 2025
    Phase
    Phase 1
    Run by
    MapKure, LLC
    Registry record
    NCT06194877
  7. Terminated

    Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

    Reason given in the registry

    “Lack of Efficacy”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2025.

    Ended
    Aug 2024
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT03610490
  8. Withdrawn

    Study of OB-002 in Patients With Refractory Metastatic Cancer

    Reason given in the registry

    “study terminated due to changes in the drug development plan”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2025.

    Ended
    Aug 2025
    Phase
    Phase 1
    Run by
    Orion Biotechnology Polska Sp. z o.o.
    Registry record
    NCT05940844
  9. Terminated

    Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    Reason given in the registry

    “Formulation challenges”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2025.

    Ended
    Mar 2025
    Phase
    Phase 1
    Run by
    Mirati Therapeutics Inc.
    Registry record
    NCT05737706
  10. Terminated

    Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Apr 2025.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    Elevation Oncology
    Registry record
    NCT04383210
  11. Suspended

    Clinical Validation of Multimodal Digestive Endoscopy

    Reason given in the registry

    “At present, this exploratory study has preliminarily achieved the set goals, and the subsequent data analysis is currently underway to determine whether it is necessary to continue recruiting participants.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2025.

    Ended
    Apr 2025
    Run by
    Xijing Hospital of Digestive Diseases
    Registry record
    NCT05575765
  12. Terminated

    Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

    Reason given in the registry

    “Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient management in the majority of centers, the IDMC experts recommended halting inclusion in the SOREGATT study with immediate effect.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2025.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    UNICANCER
    Registry record
    NCT04450836
  13. Terminated

    Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

    Reason given in the registry

    “DSMC-directed closure”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Mar 2025.

    Ended
    Nov 2023
    Phase
    Phase 1
    Run by
    University of Iowa
    Registry record
    NCT04108481
  14. Suspended

    Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites

    Reason given in the registry

    “Pilot study findings pointed to a overhaul in study design”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Mar 2025.

    Phase
    Phase 2
    Run by
    UMC Utrecht
    Registry record
    NCT05375708
  15. Terminated

    Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

    Reason given in the registry

    “The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not support the trial's purpose.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Mar 2025.

    Ended
    Jan 2025
    Phase
    Phase 2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04952753
  16. Withdrawn

    A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

    Reason given in the registry

    “The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Mar 2025.

    Ended
    Aug 2025
    Run by
    Pfizer
    Registry record
    NCT04889495
  17. Terminated

    Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

    Reason given in the registry

    “Not meeting recruitment timelines”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Mar 2025.

    Ended
    Feb 2025
    Phase
    Phase 3
    Run by
    Peter MacCallum Cancer Centre, Australia
    Registry record
    NCT04316013
  18. Terminated

    A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

    Reason given in the registry

    “Company decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Mar 2025.

    Ended
    Nov 2023
    Phase
    Phase 1
    Run by
    Boehringer Ingelheim
    Registry record
    NCT05446129
  19. Withdrawn

    UNTIRE: Cancer-related Fatigue With Digital Treatment

    Reason given in the registry

    “loss of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2025.

    Ended
    Jan 2026
    Run by
    Dana-Farber Cancer Institute
    Registry record
    NCT05584540
  20. Terminated

    A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2025.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    Turnstone Biologics, Corp.
    Registry record
    NCT05576077
  21. Terminated

    Study of rSIFN-co for Patients With Advanced Solid Tumors

    Reason given in the registry

    “Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Feb 2025.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Sichuan Huiyang Life Science and Technology Corporation
    Registry record
    NCT02464007
  22. Terminated

    Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

    Reason given in the registry

    “slow accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2025.

    Ended
    Oct 2024
    Phase
    Early phase 1
    Run by
    Mayo Clinic
    Registry record
    NCT04213794
  23. Terminated

    TATE and KN046 in MCRC

    Reason given in the registry

    “Business Operation Strategy Adjustment”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Feb 2025.

    Ended
    Jan 2025
    Phase
    Phase 2
    Run by
    Zhejiang Raygene Pharmaceuticals Co., Ltd
    Registry record
    NCT06834399
  24. Terminated

    Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

    Reason given in the registry

    “This was a strategic business decision. There were no safety concerns contributing to this decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Feb 2025.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Incyte Corporation
    Registry record
    NCT05909995
  25. Terminated

    Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

    Reason given in the registry

    “Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    Biomea Fusion Inc.
    Registry record
    NCT05631574
  26. Terminated

    A Study of SGN-STNV in Advanced Solid Tumors

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Seagen Inc.
    Registry record
    NCT04665921
  27. Terminated

    Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

    Reason given in the registry

    “enrollment too slow”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2025.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Centre Hospitalier Universitaire de Besancon
    Registry record
    NCT03117972
  28. Withdrawn

    Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

    Reason given in the registry

    “Per drug sponsor request.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Feb 2025.

    Phase
    Phase 2
    Run by
    Ibrahim Halil Sahin
    Registry record
    NCT06365970
  29. Withdrawn

    Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer

    Reason given in the registry

    “Study was not able to enroll any subjects”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2025.

    Ended
    Jan 2026
    Phase
    Phase 1/2
    Run by
    University of Alabama at Birmingham
    Registry record
    NCT03764137
  30. Terminated

    A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients

    Reason given in the registry

    “lack of enrolment”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jan 2025.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    Ente Ospedaliero Ospedali Galliera
    Registry record
    NCT03047837

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.